StockNews.com analysts have started covering stocks of ENT Intersection (NASDAQ:XENT – Get Assessment) in a research note published Saturday. The brokerage has set a “sell” rating on the medical equipment supplier’s stock.
Shares of Intersect ENT opened at $28.24 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.88 and a debt ratio of 6.89. The company has a market capitalization of $954.91 million, a P/E ratio of -5.90 and a beta of 1.45. Intersect ENT has a fifty-two week low of $15.92 and a fifty-two week high of $28.25. The company has a 50-day moving average price of $28.08 and a 200-day moving average price of $27.61.
A number of hedge funds have recently changed their holdings of XENT. FMR LLC increased its stake in Intersect ENT by 1,863.8% in the first quarter. FMR LLC now owns 632,451 shares of the medical equipment supplier valued at $20,334,000 after acquiring an additional 600,246 shares during the period. Morgan Stanley increased its position in Intersect ENT shares by 1.0% during the second quarter. Morgan Stanley now owns 166,185 shares of the medical equipment supplier worth $2,839,000 after buying 1,718 additional shares during the period. Royal Bank of Canada increased its position in Intersect ENT shares by 6.8% during the second quarter. Royal Bank of Canada now owns 8,780 shares of the medical equipment supplier worth $150,000 after buying an additional 558 shares during the period. Invesco Ltd. increased its position in Intersect ENT shares by 21.9% during the second quarter. Invesco Ltd. now owns 19,590 shares of the medical equipment supplier worth $334,000 after purchasing an additional 3,522 shares during the period. Finally, Geode Capital Management LLC increased its position in Intersect ENT shares by 2.2% during the third quarter. Geode Capital Management LLC now owns 566,426 shares of the medical equipment supplier worth $15,406,000 after purchasing an additional 12,023 shares during the period. Institutional investors hold 92.47% of the company’s shares.
About Intersect ENT (Get a rating)
Intersect ENT, Inc operates as an ENT medical technology company in the United States. The company offers PROPEL, a steroid-releasing implant to open the surgically enlarged sinus; PROPEL Mini, a release implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid-releasing implant for the treatment of ostia or openings of the frontal and maxillary sinuses of dependent sinuses.
Get news and reviews for Intersect ENT Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Intersect ENT and related companies with MarketBeat.com’s free daily email newsletter.